Current status of vaccine development against leishmaniasis

Abstract

Abstract:

Leishmaniasis is a zoonotic disease caused by Leishmania parasites. Currently, leishmaniasis has affected 12 million people in over 90 countries, with 1.3 million reported cases each year and 20-30 thousand deaths. The disease causes a large social and economic burden particularly in developing countries. Current strategies for leishmaniasis control include controlling the source of infection and drug treatment, both of which, however, cannot eliminate the disease. Effective vaccination would be an ideal approach to control leishmaniasis. Here, we review the pathogenic mechanism of Leishmania, the existing vaccines for veterinary use, and human vaccine development efforts against the disease.

Key words: Leishmania, Leishmaniasis, Vaccine

CLC Number:

R382.22

Ya-shuang CAI, Zhi-gang ZHANG, Xin WANG, Qin-jian ZHAO. Current status of vaccine development against leishmaniasis[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2017, 35(5): 499-503.

Figures/Tables 1

References 32

[1]	Visceral leishmaniasis: WHO publishes validation document as countries approach elimination[DB/OL]. New Delhi:2016[2017-04-10].
	leishmaniasis_WHO_publishes_validation_document/en/.
[2]	口岸传染病疫情风险监测一周概览(2016年8月13日-8月19日) [DB/OL]. 北京: 2016[2017-04-22]. .
[3]	多国利什曼病疫情[DB/OL]. 北京: 2016[2017-04-20]. .
[4]	WHO and Gilead Sciences extend collaboration against visceral leishmaniasis[DB/OL], Geneva:2016[2017-04-23].
	extend_collaboration/en/.
[5]	管立人. 我国内脏利什曼病的现状和对防治工作的展望[J]. 中国寄生虫学与寄生虫病杂志, 2009, 27(5): 394-397.
[6]	彭卫萍, 钟妮娜, 徐顶, 等. 2010年四川省黑热病疫区利什曼原虫家犬感染情况的调查[J]. 中国兽医科学, 2012, 42(1): 93-96.
[7]	王立英, 曾祥嫚, 伍卫平, 等. 新疆喀什地区人群内脏利什曼病血清流行病学调查[J]. 中国病原生物学杂志, 2013, 8(12): 1121-1123.
[8]	伊斯拉音·乌斯曼, 阿迪力·司马义, 凯赛尔·克尤木, 等. 2014年新疆伽师县内脏利什曼病暴发的调查分析[J]. 中国寄生虫学与寄生虫病杂志, 2015, 33(5): 357-361.
[9]	余大为, 丁国武, 格鹏飞, 等. 2005-2014年甘肃省内脏利什曼病流行情况的回顾性分析[J]. 中国寄生虫学与寄生虫病杂志, 2015, 33(3): 208-211.
[10]	李金福, 陈建平, 田玉, 等. 杜氏利什曼原虫无鞭毛体蛋白基因重组质粒的免疫原性研究[J]. 中国寄生虫学与寄生虫病杂志, 2011, 29(2): 122-125.
[11]	Faleiro RJ, Kumar R, Hafner LM, et al. Immune regulation during chronic visceral leishmaniasis[J]. PLoS Negl Trop Dis, 2014, 8(7): e2914.
[12]	Selvapandiyan A, Dey R, Nylen S, et al. Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis[J]. J Immunol, 2009, 183(3): 1813-1820.
[13]	Fiuza JA, Santiago Hda C, Selvapandiyan A, et al. Induction of immunogenicity by live attenuated Leishmania donovani centrin deleted parasites in dogs[J]. Vaccine, 2013, 31(14): 1785-1792.
[14]	Fiuza JA, Gannavaram S, Santiago Hda C, et al. Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum[J]. Vaccine, 2015, 33(2): 280-288.
[15]	Khamesipour A, Dowlati Y, Asilian A, et al. Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis[J]. Vaccine, 2005, 23(28): 3642-3648.
[16]	Mayrink W, da Costa CA, Magalhães PA, et al. A field trial of a vaccine against American dermal leishmaniasis[J]. Trans R Soc Trop Med Hyg, 1979, 73(4): 385-387.
[17]	Thakur A, Kaur H, Kaur S.Evaluation of the immunoproph-ylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis[J]. Parasitol Int, 2015, 64(1): 70-78.
[18]	Thakur A, Kaur H, Kaur S.Studies on the protective efficacy of freeze thawed promastigote antigen of Leishmania donovani along with various adjuvants against visceral leishmaniasis infection in mice[J]. Immunobiology, 2015, 220(9): 1031-1038.
[19]	Ramírez L, Santos DM, Souza AP, et al. Evaluation of immune responses and analysis of the effect of vaccination of the Leishmania major recombinant ribosomal proteins L3 or L5 in two different murine models of cutaneous leishmaniasis[J]. Vaccine, 2013, 31(9): 1312-1319.
[20]	Martins VT, Lage DP, Duarte MC, et al. A new leishmania-specific hypothetical protein, LiHyT, used as a vaccine antigen against visceral leishmaniasis[J]. Acta Trop, 2016, 154: 73-81.
[21]	Nogueira FS, Moreira MA, Borja-Cabrera GP, et al. Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs[J]. Vaccine, 2005, 23(40): 4805-4810.
[22]	Saraiva EM, de Figueiredo Barbosa A, Santos FN, et al.The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine[J]. Vaccine, 2006, 24(13): 2423-2431.
[23]	Duthie MS, Raman VS, Piazza FM, et al. The development and clinical evaluation of second-generation leishmaniasis vaccines[J]. Vaccine, 2012, 30(2): 134-141.
[24]	Gillespie PM, Beaumier CM, Strych U, et al. Status of vaccine research and development of vaccines for leishmaniasis[J]. Vaccine, 2016, 34(26): 2992-2995.
[25]	Tabatabaie F, Mahdavi M, Faezi S, et al. Th1 platform immune responses against Leishmania major induced by thiol-specific antioxidant-based DNA vaccines[J]. Jundishapur J Microbiol, 2014, 7(2): e8974.
[26]	Das S, Freier A, Boussoffara T, et al. Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis[J]. Sci Transl Med, 2014, 6(234): 234-256.
[27]	Khamesipour A.Therapeutic vaccines for leishmaniasis[J]. Expert Opin Biol Ther, 2014, 14(11): 1641-1649.
[28]	Doroud D, Rafati S.Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems[J]. Expert Rev Vaccines, 2012, 11(1): 69-86.
[29]	宋佳林, 张雷. 反向疫苗学的及其应用研究新进展[J]. 中国病原生物学杂志, 2015, 10(9): 845-847.
[30]	Duarte MC, Lage DP, Martins VT, et al. Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis[J]. Rev Soc Bras Med Trop, 2016, 49(4): 398-407.
[31]	Duthie MS, Favila M, Hofmeyer KA, et al. Strategic evaluation of vaccine candidate antigens for the prevention of visceral leishmaniasis[J]. Vaccine, 2016, 34(25): 2779-2786.
[32]	Kumar R, Engwerda C.Vaccines to prevent leishmaniasis[J]. Clin Transl Immunology, 2014, 3(3): e13.

候选疫苗	政府临床实验编号	临床阶段	针对病症	药物联用
Alum-ALM + BCG	NCT00429715	Ⅱ期	皮肤利什曼病	-
Alum-ALM + BCG	NCT00429780	Ⅱ期/Ⅲ期
Leish-111F + MPL-SE	NCT00111553	Ⅰ期	皮肤利什曼病	-
	NCT00121849	Ⅰ期
	NCT00121862	Ⅱ期
	NCT00111514	Ⅰ期	黏膜利什曼病
	NCT00486382	Ⅰ期	内脏利什曼病/ 黑热病后皮肤利什曼病
LEISH-F2 + MPL-SE	NCT01011309	Ⅱ期	皮肤利什曼病	葡萄糖酸锑钠
LEISH-F2 + MPL-SE	NCT00982774	Ⅰ期	黑热病后皮肤利什曼病	-
LEISH-F3 + GLA-SE	NCT01484548	Ⅰ期	内脏利什曼病	-
LEISH-F3 + GLA-SE/LEISH- F3 + MPL-SE	NCT01751048	Ⅰ期	内脏利什曼病	-
LEISH-F3 + SLA-SE/LEISH- F3 + GLA-SE	NCT02071758	Ⅰ期	内脏利什曼病	-
ChAd63-KH	NCT02894008	Ⅱ期	黑热病后皮肤利什曼病	-